Azitra, Inc. (AZTR) Stock Price & Analysis

Azitra, Inc. (AZTR) fell 0.28% to USD 0.18 as of September 8, 2026 at 06:23 UTC, according to Nexqual real-time market data.

AZTR last closed at USD 0.18; the session ranged USD 0.17–0.18 on volume of 320,266 shares. Market capitalization is —, with a 52-week range of USD 0.1–1.09 (ASE). Source: Nexqual, September 8, 2026 at 06:23 UTC.

Key Statistics (as of September 8, 2026 at 06:23 UTC)

Technical Analysis (AZTR)

Nexqual's technical model rates AZTR "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 06:23 UTC.

Analyst Ratings (AZTR)

Wall Street analysts rate AZTR "None" based on 2 analysts, with a mean price target of USD 0.78 (range USD 0.55–1), per Nexqual as of September 8, 2026 at 06:23 UTC.

From Azitra, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• In preclinical studies, we have shown that S. epidermidis homes to layers below the stratum corneum and delivers proteins into the deeper epidermis. 5 To expand upon our recombinant protein construction capabilities, we have acquired an exclusive license to proprietary technology that disguises our genetically engineered DNA sequences to enable the production of proteins in previously intractable bacterial species.
• Since our formation, we have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics.
• We have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics.
• To address this challenge, we have developed a proprietary process capable of facilitating protein delivery in a manner that bypasses the normally impenetrable stratum corneum.

Partnerships

• Through our collaboration with Chemia Biosciences, we are able to use their proprietary genomic and peptidomic artificial intelligence and machine learning system, NRPMiner, to develop and confirm natural product predictions of the proteins, peptides and small molecules that are generated by our proprietary bacterial library.
• Our collaboration with the Carnegie Mellon team takes advantage of the power of whole genome sequencing.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:23 UTC. This page is informational and not investment advice.